Literature DB >> 32195628

Heparin-induced thrombocytopenia (HIT): Review of incidence, diagnosis, and management.

Marie Hogan1, Jeffrey S Berger2.   

Abstract

Heparin-induced thrombocytopenia (HIT) is a life and limb-threatening complication of heparin exposure. Here, we review the pathogenesis, incidence, diagnosis, and management of HIT. The first step in thwarting devastating complications from this entity is to maintain a high index of clinical suspicion, followed by an accurate clinical scoring assessment using the 4Ts. Next, appropriate stepwise laboratory testing must be undertaken in order to rule out HIT or establish the diagnosis. In the interim, all heparin must be stopped immediately, and the patient administered alternative anticoagulation. Here we review alternative anticoagulation choice, therapy alternatives in the difficult-to-manage patient with HIT, and the problem of overdiagnosis.

Entities:  

Keywords:  heparin-induced thrombocytopenia (HIT); hypercoagulable states; venous thromboembolism (VTE)

Year:  2020        PMID: 32195628     DOI: 10.1177/1358863X19898253

Source DB:  PubMed          Journal:  Vasc Med        ISSN: 1358-863X            Impact factor:   3.239


  14 in total

1.  Lower Limb Paralysis as Initial Presentation of Arterial Embolism Secondary to Heparin-Induced Thrombocytopenia after Hip Fracture - a Case Report.

Authors:  Petros Kapsetakis; Georgios Magarakis; Constantinos Chaniotakis; Phaedon D Zavras; Georgios Kavalaris; Christos Koutserimpas; Kalliopi Alpantaki
Journal:  Maedica (Bucur)       Date:  2022-06

2.  Arterial and Venous Thrombosis From Delayed-Onset Heparin-Induced Thrombocytopenia.

Authors:  Abhinandan R Chittal; Ajay Kumar; Shiavax J Rao; Pallavi Lakra; Natalia Nacu
Journal:  J Community Hosp Intern Med Perspect       Date:  2022-07-04

Review 3.  Epidemiology and prevention of venous thromboembolism.

Authors:  Pamela L Lutsey; Neil A Zakai
Journal:  Nat Rev Cardiol       Date:  2022-10-18       Impact factor: 49.421

4.  A Case Report and Literature Review on Argatroban Refractory Heparin-Induced Thrombocytopenia.

Authors:  Imad U Deen; Swati A Jha; Sadaf Mustafa
Journal:  J Community Hosp Intern Med Perspect       Date:  2022-09-09

5.  Treatment of ChAdOx1 nCoV-19 Vaccine-Induced Immune Thrombotic Thrombocytopenia Related Acute Ischemic Stroke.

Authors:  Jana Kenda; Dimitrij Lovrič; Matevž Škerget; Nataša Milivojević
Journal:  J Stroke Cerebrovasc Dis       Date:  2021-08-28       Impact factor: 2.136

Review 6.  Heparin-Induced Thrombocytopenia: A Focus on Thrombosis.

Authors:  Gowthami M Arepally; Anand Padmanabhan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-12-03       Impact factor: 8.311

Review 7.  Vaccine-induced immune thrombotic thrombocytopenia after vaccination against Covid-19: A clinical dilemma for clinicians and patients.

Authors:  Zeinab Mohseni Afshar; Arefeh Babazadeh; Alireza Janbakhsh; Mandana Afsharian; Kiarash Saleki; Mohammad Barary; Soheil Ebrahimpour
Journal:  Rev Med Virol       Date:  2021-07-01       Impact factor: 11.043

8. 

Authors:  Melissa Jones; Annie Boisvert; Jennifer Landry; Paul F Petrasek
Journal:  CMAJ       Date:  2021-07-05       Impact factor: 8.262

Review 9.  Superior outcomes with Argatroban for heparin-induced thrombocytopenia: a Bayesian network meta-analysis.

Authors:  Giorgia Colarossi; Nicola Maffulli; Andromahi Trivellas; Heike Schnöring; Nima Hatam; Markus Tingart; Filippo Migliorini
Journal:  Int J Clin Pharm       Date:  2021-03-28

10.  Heparin-induced thrombocytopenia in extra-corporeal membrane oxygenation: epidemiology, outcomes, and diagnostic challenges.

Authors:  Akram M Zaaqoq; Robert C Brammer; Chee M Chan; Andrew F Shorr
Journal:  J Thromb Thrombolysis       Date:  2021-08-02       Impact factor: 5.221

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.